PROMO!
First order? Get 10% OFF with this code: 1storder
Hexarelin is a synthetic hexapeptide classified as a peptidyl growth hormone secretagogue and member of the growth hormone-releasing peptide (GHRP) family.
Hexarelin is a synthetic hexapeptide that belongs to the growth hormone-releasing peptide (GHRP) family and has two D-configured residues and a C-terminal amide. Hexarelin and the GHRP-6 protein are structurally identical due to the integration of 2-methyl-D-tryptophan at the second residue position.
Laboratory research has investigated Hexarelin principally in relation to growth hormone secretagogue receptor (GHS-R) pharmacology and peptide–receptor signaling. Early experimental work characterised Hexarelin as a GHRP-6 analogue and examined its activity in receptor-associated cellular systems.
From a molecular-research perspective, Hexarelin provides a defined peptide structure for investigating structure–activity relationships, receptor recognition and intracellular signaling associated with growth hormone secretagogue peptides. Its substitution of D-tryptophan with a 2-methyl derivative also provides a structural basis for comparative studies with related GHRP compounds
A synthetic linear hexapeptide made up of six amino acid residues is called hexarelin. D-phenylalanine at position 5, 2-methyl-D-tryptophan at position 2, and a C-terminally amidated lysine residue are all part of its structure. These distinct structural characteristics set hexarelin apart from peptides that are similarly related, including GHRP-6.
Hexarelin does not contain disulfide bonds or glycosylation. Its defined amino-acid sequence, D-residue stereochemistry, methylated tryptophan and C-terminal amidation are therefore important parameters when establishing molecular identity. These characteristics can be evaluated using complementary analytical techniques such as chromatography and mass spectrometry.
The growth hormone secretagogue receptor type 1a (GHS-R1a) signaling system is the main context in which hexarelin has been studied as a synthetic ligand. Hexarelin has been utilized in laboratory receptor-expression models to study GHS-R1a, a G-protein-coupled receptor (GPCR), and related intracellular signaling mechanisms.
GHS-R1a-Associated Signaling
Phospholipase C (PLC)-dependent signaling is linked to GHS-R1a activation. Phosphoinositide turnover and the production of intracellular second messengers are two aspects of this receptor pathway that provide quantifiable biochemical endpoints for investigating ligand–receptor interactions in carefully regulated experimental settings.
Intracellular Calcium Mobilisation
Hexarelin has also been investigated in relation to intracellular Ca²⁺ signalling. Experiments using cells expressing human GHS-R1a have measured changes in intracellular calcium following Hexarelin exposure, providing a laboratory model for examining receptor activation and receptor desensitisation.
Receptor-Binding and Structure–Activity Research
Hexarelin's well-defined structure also makes it pertinent to research on receptor binding and the structure–activity link. Hexarelin's interactions with molecular targets have been studied in relation to GHRP-6 and structurally modified analogs.
In addition to GHS-R1a-associated research, Hexarelin-derived ligands have been used experimentally in studies involving the CD36 scavenger receptor, providing another molecular system for investigating peptide–receptor recognition and binding selectivity.
Overall, Hexarelin provides a defined synthetic peptide for laboratory investigation of GHS-R1a receptor pharmacology, PLC-associated signalling, intracellular calcium mobilisation, receptor desensitisation and peptide structure–activity relationships. Observed molecular responses should be interpreted according to the specific receptor system, cell model and experimental conditions used.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
Hexarelin has been investigated as a synthetic ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a). Laboratory receptor systems provide a controlled framework for studying ligand binding, receptor activation and molecular signalling associated with this G-protein-coupled receptor.
Cell-based studies have used Hexarelin to examine GHS-R1a-associated intracellular signalling, including phospholipase C-linked pathways and changes in intracellular second messengers. These experiments help characterise the molecular events occurring following receptor activation under defined laboratory conditions.
Changes in intracellular Ca²⁺ provide a measurable endpoint for studying GHS-R1a activation. Hexarelin can therefore be used in receptor-expression and cell-based assays investigating calcium mobilisation and other receptor-associated signaling processes.
Additionally, hexarelin has been studied as a ligand of the CD36 scavenger receptor, offering a different mechanistic field of study from GHS-R1a signaling. Researchers may now investigate peptide–receptor recognition at the molecular level thanks to photoaffinity-labelling experiments that have revealed a particular area of CD36 linked to hexarelin binding.
Hexarelin is appropriate for structural–activity relationship (SAR) research because to its well-defined hexapeptide structure. The effects of specific amino acid substitutions on molecular recognition and binding affinity at GHS-R1a and CD36 have been studied in comparison with GHRP-6 and structurally altered analogs.
In order to examine variations in sequence, stereochemistry, receptor affinity, and molecular selectivity, hexarelin can also be contrasted with similar synthetic GHRPs. Without the need for medicinal or human-use framing, these investigations shed light on the structural characteristics controlling peptide–receptor interactions.
Hexarelin's chromatographic purity and peptide identification should both be verified analytically. To evaluate purity and separate the main peptide component from contaminants or degradation products associated to synthesis, reverse-phase HPLC (RP-HPLC) can be utilized. HPLC is also used to characterize commercial analytical standards for hexarelin.
Based on the anticipated molecular species and distinctive fragmentation behavior, LC-MS or LC-MS/MS can confirm molecular identification. Intact hexarelin has been discovered as one of the growth hormone-releasing peptides found using targeted LC-MS/MS techniques in published analytical procedures.
In addition to mass and chromatographic parameters, Hexarelin's reported stereochemistry, modified 2-methyl-D-tryptophan residue, and C-terminal amidation should be considered while recording identification. Batch-specific analytical documentation should describe lot data, purity, identification, and analytical procedure in order to aid traceability.
Hexarelin research material should be stored according to the validated conditions specified for the supplied chemical form and batch. Lyophilised peptide should remain in its original sealed container and be protected from moisture, excessive light and unnecessary temperature fluctuations. General scientific guidance for synthetic peptide reference materials emphasises that storage conditions should be established according to peptide-specific stability data rather than assumed from a universal storage temperature.
Hexarelin is a synthetic hexapeptide and is not a naturally occurring endogenous peptide. Its defined structure includes modified and D-configured amino-acid residues introduced as part of its peptide design.
2-methyl-D-tryptophan is the name given to the altered tryptophan residue located at position 2 of hexarelin. Methyl substitution and D-configuration are two of hexarelin's unique structural features that set it apart from similar peptides like GHRP-6.
Hexarelin has been investigated principally as a ligand within the growth hormone secretagogue receptor type 1a (GHS-R1a) system. Laboratory studies use this interaction to investigate peptide–receptor recognition and receptor-associated molecular signaling.
Yes. Hexarelin has also been investigated in relation to CD36, a class B scavenger receptor. This represents a molecular research area distinct from GHS-R1a and is useful for studying peptide–receptor binding and molecular selectivity.
Both Hexarelin and GHRP-6 are classed as synthetic hexapeptides, however Hexarelin contains 2-methyl-D-tryptophan at position 2. Its defined sequence is H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH₂.
RP-HPLC can be used to assess chromatographic purity, whilst LC-MS or high-resolution mass spectrometry can provide complementary confirmation of molecular identity. The defined Hexarelin molecule has a monoisotopic mass of approximately 886.460 Da.
Hexarelin contains specifically configured amino-acid residues, including D-2-methyl-tryptophan and D-phenylalanine. Correct stereochemistry forms part of the peptide’s molecular identity, so molecular mass alone does not fully establish that a sample has the intended stereochemical structure.
Hexarelin can be compared with related GHRPs through sequence analysis, receptor-binding assays, structure–activity studies and analytical characterisation. Such comparisons allow researchers to investigate how defined structural changes—particularly the 2-methyl substitution at the second residue—relate to differences in molecular recognition under controlled experimental conditions.
Hexarelin is intended for research and laboratory use only. It is not intended for human or animal consumption and is not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of any disease or condition. The information provided on this page is limited to scientific and technical information about Hexarelin, including its molecular characteristics, analytical properties, and areas of laboratory research. Nothing on this page is intended to provide medical, clinical, therapeutic, or dosing guidance.
